Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Paglialunga

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Clinical and Translational Science|March 10, 2026
QT Myopia and Cardiac Safety: Expanding the Aperture of Arrhythmia Assessment in Early Phase Drug DevelopmentRobert M Lester, Katherine Clark, Sabina Paglialunga
International Journal of Molecular Sciences|March 20, 2019
QT Assessment in Early Drug Development: The Long and the Short of ItRobert M Lester, Sabina Paglialunga, Ian A Johnson
Drug, Healthcare and Patient Safety|May 2, 2018
Evaluating cardiac risk: exposure response analysis in early clinical drug developmentJulie Grenier, Sabina Paglialunga, Bruce H Morimoto, et al.
Journal of Pharmacological and Toxicological Methods|June 8, 2019
Translatability of the S7A core battery respiratory safety pharmacology studies: Preclinical respiratory and related clinical adverse eventsSabina Paglialunga, Bruce H Morimoto, Matthew Clark, et al.
Diabetologia|March 11, 2015
In adipose tissue, increased mitochondrial emission of reactive oxygen species is important for short-term high-fat diet-induced insulin resistance in miceSabina Paglialunga, Alison Ludzki, Jared Root-McCaig, et al.
Clinical Pharmacology and Therapeutics|May 20, 2022
Rifampin Drug-Drug-Interaction Studies: Reflections on the Nitrosamine Impurities IssueAernout van Haarst, Stephen Smith, Clare Garvin, et al.
Clinical Pharmacology in Drug Development|February 15, 2018
Tracking the Sugar Rush: Incorporating Continuous Glucose Monitoring Into Multisite Early Clinical Research With Type 2 Diabetes SubjectsSabina Paglialunga, Bruce H Morimoto, Amparo de la Peña, et al.
Clinical Pharmacology and Therapeutics|May 3, 2024
Should You Run a Dedicated TQT Study? Sponsor and Regulatory Considerations on Substitution Pathways to Assess QT LiabilityRobert M Lester, Caroline Engel, Aernout D van Haarst, et al.
Expert Review of Clinical Pharmacology|December 22, 2016
Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelinesSabina Paglialunga, Elliot Offman, Nita Ichhpurani, et al.
BMC Physiology|April 27, 2010
The effects of acylation stimulating protein supplementation VS antibody neutralization on energy expenditure in wildtype miceSabina Paglialunga, Alexandre Fisette, Mercedes Munkonda, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Clinical and Translational Science|March 10, 2026
QT Myopia and Cardiac Safety: Expanding the Aperture of Arrhythmia Assessment in Early Phase Drug DevelopmentRobert M Lester, Katherine Clark, Sabina Paglialunga
International Journal of Molecular Sciences|March 20, 2019
QT Assessment in Early Drug Development: The Long and the Short of ItRobert M Lester, Sabina Paglialunga, Ian A Johnson
Drug, Healthcare and Patient Safety|May 2, 2018
Evaluating cardiac risk: exposure response analysis in early clinical drug developmentJulie Grenier, Sabina Paglialunga, Bruce H Morimoto, et al.
Journal of Pharmacological and Toxicological Methods|June 8, 2019
Translatability of the S7A core battery respiratory safety pharmacology studies: Preclinical respiratory and related clinical adverse eventsSabina Paglialunga, Bruce H Morimoto, Matthew Clark, et al.
Diabetologia|March 11, 2015
In adipose tissue, increased mitochondrial emission of reactive oxygen species is important for short-term high-fat diet-induced insulin resistance in miceSabina Paglialunga, Alison Ludzki, Jared Root-McCaig, et al.
Clinical Pharmacology and Therapeutics|May 20, 2022
Rifampin Drug-Drug-Interaction Studies: Reflections on the Nitrosamine Impurities IssueAernout van Haarst, Stephen Smith, Clare Garvin, et al.
Clinical Pharmacology in Drug Development|February 15, 2018
Tracking the Sugar Rush: Incorporating Continuous Glucose Monitoring Into Multisite Early Clinical Research With Type 2 Diabetes SubjectsSabina Paglialunga, Bruce H Morimoto, Amparo de la Peña, et al.
Clinical Pharmacology and Therapeutics|May 3, 2024
Should You Run a Dedicated TQT Study? Sponsor and Regulatory Considerations on Substitution Pathways to Assess QT LiabilityRobert M Lester, Caroline Engel, Aernout D van Haarst, et al.
Expert Review of Clinical Pharmacology|December 22, 2016
Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelinesSabina Paglialunga, Elliot Offman, Nita Ichhpurani, et al.
BMC Physiology|April 27, 2010
The effects of acylation stimulating protein supplementation VS antibody neutralization on energy expenditure in wildtype miceSabina Paglialunga, Alexandre Fisette, Mercedes Munkonda, et al.
Pageof 5